Reshaping Medical Affairs: delivering value to KOLs and payers
[Lowest Price Guaranteed: $695]
Published by FirstWord Pharma: 21 Aug 2014 | 150 | In Stock
Related Topics: Medical
Historically, the key role of Medical Affairs was supporting the initial regulatory approval. Today, that’s only the first hurdle. Due to increasing healthcare costs and the need to make difficult value-based decisions, the data package is extensive. Pharmaceutical companies must demonstrate the value of products through safety and efficacy trials, health economics trials and comparative efficacy trials, and medical affairs is taking on the bulk of the responsibility in providing that additional data package.
As the Medical Affairs role evolves, more questions arise. And with each company defining the role differently, it is creating confusion.
Reshaping Medical Affairs: delivering value to KOLs and payers provides answers to pressing questions the industry is facing. This report includes primary research from within the pharmaceutical industry and related consulting.
Key Questions Answered
Table of Contents
for Reshaping Medical Affairs: delivering value to KOLs and payers
2.Research methodology and objectives
3.The evolution of medical affairs
3.1.Defining the key functions of medical affairs
3.1.1.Data generation and research
3.2.The evolving role of medical affairs
3.2.1.The major changes in medical affairs in recent years
3.2.2.The relationship between medical affairs, market access and commercial
184.108.40.206.Strategic interaction between departments
220.127.116.11.The need for medical affairs approval of commercial information
3.3.1.Becoming more proactive
3.3.2.Training and education
3.3.3.Investigator initiated trials
3.3.4.Pharma sponsored phase IV studies
4.Building valued relationships with stakeholders
4.1.Demonstrating value to stakeholders
4.1.1.Adapting as healthcare provision changes
4.2.The role of medical affairs in the payer relationship
4.2.1.Collaboration between medical affairs and market access
4.2.2.Demonstrating value to payers
4.2.3.Answering payer questions
4.2.4.Accountable Care Organisations (ACOs)
4.2.5.Health economics outcomes research
4.3.Engaging with patient advocacy groups
4.3.1.Regulation on the promotion of medicinal products to patients
4.4.Engaging with physicians
4.4.1.The MSL role in KOL relationships
4.4.2.At what stage of development does KOL engagement begin?
4.4.3.Interacting with physicians when they have questions
4.4.4.Transparency regulation – what has changed since the Sunshine Act?
18.104.22.168.Could interpretation of the Sunshine Act stifle future innovation in the US?
4.5.Cross-boundary regulatory compliance
4.6.Transparency, training and compliance tracking
4.7.Communicating via appropriate channels
4.8.1.Evaluating quality and value
4.8.2.Have we changed patients' lives?
Number of Pages
|Title||Date Published||Price from||More Details|
|Reshaping the Pharma Sales Force: A blueprint for contemporary sales and service models|
IntroductionThe long-standing, universal model of the pharma sales force has been declared dead. Sel...
|01 Sep 2015 by FirstWord Pharma||USD $695||More Info|
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.